The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).

This is an open-label, single-arm, Phase II feasibility study to examine the proportion of patients that complete neoadjuvant therapy followed by curative-intent surgery. Patients with high-risk, resectable, intrahepatic cholangiocarcinoma will receive the combination of gemcitabine, cisplatin, and durvalumab for 4 cycles in the neoadjuvant setting before undergoing surgical resection. After surgery, patients will receive the combination therapy of gemcitabine, cisplatin, and durvalumab for 4 cycles in the adjuvant setting.

Phase II trial evaluating the combination of XL-092 with durvalumab and tremelimumab in unresectable HCC. This phase II trial design will be preceded by a safety lead in of 9-12 patients.